Nutrition Track Agenda Announced for 4th Annual Translational Microbiome Conference
MINNEAPOLIS (PRWEB) March 29, 2018 -- Arrowhead Publishers released a parallel nutrition track agenda for the 4th Annual Translational Microbiome Conference, scheduled April 18-20 in Boston. The conference is designed to bring together scientists at the forefront of microbiome research with pioneering business leaders at companies generating microbiome-based medical solutions. Sponsored by Nestlé Health Science, the nutrition track focuses on issues and learnings around development of medical food, with specific examples of innovative nutritional treatments for IBD and obesity. The focused sessions will cover current regulatory criteria for medical food, as well as common regulatory challenges faced by companies innovating in nutrition science.
“Nutrition science is advancing at such a rapid rate, and regulation is complex and dynamic,” said John Waslif, Managing Director of Arrowhead Publishers. “We designed the nutrition track at our 4th Annual Translational Microbiome Conference as a forum for thought leaders to share best practices and insights, because collaboration in this environment can help speed development and clear hurdles.”
A growing body of research showcases the role nutritional solutions can play in prevention and treatment of many common issues, and nutrition track sessions are developed to provide translational insight to other companies navigating that path.
Nutrition track sessions include:
Eating for Two: Developing Nutritional Interventions and Naturally Derived Products that Consider Host and Microbial Requirements for Improved Human Health
Paul Giannasca, Ph.D., Global Scientific Lead, GI Health, Nestlé Health Science
The design of new nutritional measures and therapies will be advanced through an integrated approach incorporating knowledge of host nutrition, GI biology, our bacterial symbionts and the many intersecting metabolic pathways. The presentation will summarize ongoing efforts to develop nutritional interventions for IBD, the use of traditional Chinese botanicals to develop drugs for GI health and the mining of bacterial culture collections for beneficial strains.
Diet, the Gut Microbiome, and its Metabolome in Inflammatory Bowel Disease: Therapeutic Opportunities
Elliot Friedman, Ph.D., Senior Research Investigator, Division of Gastroenterology, Technical Director, Microbial Culture & Metabolomics Core, PennCHOP Microbiome Program, Perelman School of Medicine, University of Pennsylvania
The environment of the gut, namely the microbiota and diet, plays an important role in the pathogenesis of the inflammatory bowel diseases (IBD) that afflict approximately 3 million patients in the U.S. alone. Characterization of the impact of diet on both the composition of the gut microbiota as well as the metabolites that are produced might lead to the discovery of alternative strategies to treat IBD by engineering the environment of the gut. Using defined formula diets as a therapeutic probe, we describe several human subject studies that are designed to help determine better diets for patients with IBD that can be used to treat and/or prevent the recurrence of active disease.
Nutritional Approaches that impact the microbiome: Hype, Hope, and Regulatory Realities of Medical Foods
Tim Morck, Ph.D., President, Spectrum Nutrition
When research shows an impact of a product on the microbiome, with positive outcomes on certain markers of health or disease, what regulatory category does it fall under for commercialization, and what claims are permissible? This presentation will explain current regulatory criteria for medical food, and share encouraging steps being taken to address the challenges regulators face to keep pace with rapidly advancing nutritional science.
Panel Discussion: Microbiome Products as Medical Foods: Is There a Nutritional Requirement for Bacteria?
Moderated by Bernadette Janas, Ph.D., Global Medical Affairs Lead, Nestlé Health Science
Panelists:
David Beno, Ph.D., Chief Scientific Officer, Xeno Biosciences
Colleen Cutcliffe, Ph.D., Chief Executive Officer, Whole Biome
Tim Morck, Ph.D., President, Spectrum Nutrition
This panel session will explore questions such as these:
- Is the data sufficient to establish an "ideal" microbiome composition to support health, that might permit supplemental bacteria to be considered similar to an "essential nutrient" to correct an imbalance associated with a disease?
- Is lack of enforcement by the FDA toward companies marketing supplements as medical foods in the space indicative of their stance?
- Does the FDA have the resources to address this issue and how will companies in the space be able to successfully elevate the priority of this issue to a level where the FDA commits to take action to clarify this area?
- How should companies conduct a risk/benefit analysis when considering launching a new product in an uncertain regulatory space?
Pharmacological Mimicry of Gastric Bypass Microbiome to Treat Obesity
David Beno, Ph.D., Chief Scientific Officer, Xeno Biosciences
Xeno Biosciences is leveraging nascent bariatric surgery/microbiome science to develop XEN-101. We have proposed the "air hypothesis" as a mechanism to explain the profound weight loss and the associated microbiome shifts observed after gastric bypass surgery. We created XEN-101, a first-in-class, oral anti-obesity medicine. XEN-101 has preclinical and initial clinical pilot efficacy data, demonstrating substantial weight loss and corresponding shifts in the gut microbiome. Xeno is currently in early development preparing for Phase I studies.
View the full agenda for the 4th Annual Translational Microbiome Conference at http://www.microbiomeconference.com.
Sponsors and Exhibitors can showcase products and branding in an environment designed to facilitate professional networking. Learn more via http://www.microbiomeconference.com/sponsor-exhibit.
# # #
Arrowhead Publishers brings life sciences industry professionals together to help move research forward through learning, networking and professional growth. Arrowhead focuses on offering thoughtfully curated speakers, new research industry trends, case studies, emerging discoveries and the future focus of the biotech and pharmaceutical industries. Arrowhead conferences cover clinical development and cutting-edge research, regulatory issues and market dynamics, therapeutics, drug discovery and positioning, and emerging technologies for both clinicians and pharmaceutical professionals.
John Waslif, Arrowhead Publishers, http://www.microbiomeconference.com, 866-945-0263 (x 700), [email protected]
Share this article